FDA Approves New High-Dose Spinraza Regimen for SMA, Bolstering Biogen's Key Drug
BIIB sits 68% above its 52-week low of $110.035.
Summary
The FDA has approved a new high-dose regimen of Biogen's Spinraza (nusinersen) for Spinal Muscular Atrophy (SMA), with availability expected in the U.S. in the coming weeks. This regulatory approval is a significant positive development for Biogen, as Spinraza is a cornerstone product and a major revenue contributor. The new regimen could enhance the drug's competitive profile and potentially expand its market share or extend its revenue longevity in the competitive SMA treatment landscape. This news follows other recent positive developments for Biogen, including a significant licensing agreement and positive Phase 2 clinical trial results for another pipeline asset, indicating continued progress in its product portfolio. Investors will be watching for the commercial uptake of this new regimen and its impact on future Spinraza sales.
At the time of this announcement, BIIB was trading at $185.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.